CTLA4 and colorectal carcinoma: The programmed cell death protein 1 (PD1) antibodies pembrolizumab and nivolumab and the combination of nivolumab and ipilimumab (a cytotoxic T-lymphocyte associated protein 4 (CTLA4) antibody) have elicited effective and durable responses, and their use for treating CRC has been approved by the US Food and Drug Administration (FDA) (22).